Avian Influenza – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Avian Influenza – Drugs In Development, 2024 report and make more profitable business decisions.
Avian influenza, commonly referred to as bird flu, is a viral infection that primarily affects birds, especially poultry such as chickens and turkeys. Various strains of avian influenza viruses exist, some of which can cause severe illness in birds and, in certain cases, pose a risk to human health. Avian influenza viruses belong to the influenza A virus family and are classified based on surface proteins: hemagglutinin (H) and neuraminidase (N). The H5, H7, and H9 subtypes are of particular concern due to their potential to cause severe disease in birds and occasionally transmit to humans. Avian influenza viruses primarily circulate among birds and can spread through direct contact with infected birds, their feces, respiratory secretions, or contaminated surfaces. Human infections often occur through close contact with infected birds or environments contaminated with the virus. While most avian influenza viruses do not infect humans, certain strains, particularly H5N1, H7N9, and others, have caused sporadic cases of severe illness and even death in humans. Human infections are rare but can occur following direct contact with infected birds, particularly in settings such as live bird markets or farms.
The Avian Influenza drugs in development market research report provide comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Avian Influenza and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Avian Influenza | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 60 molecules, with 42 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Avian Influenza therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Avian Influenza pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Avian Influenza treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abzyme Therapeutics LLCAIM ImmunoTech Inc
Aphios Corp
AusBio Ltd
Beijing Tiantan Biological Products Co Ltd
BlueWillow Biologics Inc
Butantan Institute
Celdara Medical LLC
Chicago Biosolutions Inc
CHO Pharma Inc
Cocrystal Pharma Inc
Codagenix Inc
CSL Ltd
CytoAgents Inc
EpiVax Inc
Evrys Bio
FluGen Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
Gamma Vaccines Pty Ltd
Georgia State University
German Center for Infection Research
Global BioLife Inc Ltd
Greffex Inc
GSK plc
Guangdong Raynovent Biotech Co Ltd
Hualan Biological Bacterin Co Ltd
Inovio Pharmaceuticals Inc
Joincare Pharmaceutical Group Industry Co Ltd
Lee's Pharmaceutical Holdings Ltd
Longhorn Vaccines and Diagnostics LLC
Medigen Inc
New Amsterdam Sciences Inc
Novavax Inc
Ology Bioservices Inc
Osivax SAS
PeptiDream Inc
Pneumagen Ltd
Replikins Ltd
TaiGen Biotechnology Co Ltd
TechnoVax Inc
The Institute of Vaccines and Medical Biologicals
The National Institute of Allergy and Infectious Diseases
Tiba Biotech LLC
U.S. National Institutes of Health
University of Edinburgh
University of Hong Kong
University of Oslo
University of St. Andrews
University of Wisconsin Madison
Vacthera BioTech GmbH
Vanderbilt University
Vaxart Inc
Viramatix Sdn Bhd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Avian Influenza reports